• Pain · Dec 2012

    Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations.

    • Sandra D Comer, James P Zacny, Robert H Dworkin, Dennis C Turk, George E Bigelow, Richard W Foltin, Donald R Jasinski, Edward M Sellers, Edgar H Adams, Robert Balster, Laurie B Burke, Igor Cerny, Robert D Colucci, Edward Cone, Penney Cowan, John T Farrar, J David Haddox, Jennifer A Haythornthwaite, Sharon Hertz, Gary W Jay, Chris-Ellyn Johanson, Roderick Junor, Nathaniel P Katz, Michael Klein, Ernest A Kopecky, Deborah B Leiderman, Michael P McDermott, Charles O'Brien, Alec B O'Connor, Pamela P Palmer, Srinivasa N Raja, Bob A Rappaport, Christine Rauschkolb, Michael C Rowbotham, Cristina Sampaio, Beatrice Setnik, Marta Sokolowska, Joseph W Stauffer, and Sharon L Walsh.
    • Division on Substance Abuse, New York State Psychiatric Institute/College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA. sdc10@columbia.edu
    • Pain. 2012 Dec 1;153(12):2315-24.

    AbstractA critical component in development of opioid analgesics is assessment of their abuse liability (AL). Standardization of approaches and measures used in assessing AL have the potential to facilitate comparisons across studies, research laboratories, and drugs. The goal of this report is to provide consensus recommendations regarding core outcome measures for assessing the abuse potential of opioid medications in humans in a controlled laboratory setting. Although many of the recommended measures are appropriate for assessing the AL of medications from other drug classes, the focus here is on opioid medications because they present unique risks from both physiological (e.g., respiratory depression, physical dependence) and public health (e.g., individuals in pain) perspectives. A brief historical perspective on AL testing is provided, and those measures that can be considered primary and secondary outcomes and possible additional outcomes in AL assessment are then discussed. These outcome measures include the following: subjective effects (some of which comprise the primary outcome measures, including drug liking; physiological responses; drug self-administration behavior; and cognitive and psychomotor performance. Before presenting recommendations for standardized approaches and measures to be used in AL assessments, the appropriateness of using these measures in clinical trials with patients in pain is discussed.Published by Elsevier B.V.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.